KRAS and neoplasm: For patients with K-ras mutant tumours, treatment with CAPOX plus bevacizumab plus cetuximab resulted in worse survival outcome (Tol et al, 2009), similar to other studies where chemotherapy plus cetuximab had the worst outcome in K-ras mutant patients (Van Cutsem et al, 2008; Bokemeyer et al, 2009).